Five Compounds, One Cascade: Botanical Research on Vascular Aging

Blood vessels age in a sequence, and each step has been studied separately. Six botanical compounds turn up across that sequence, and almost none of them act at the same point.

What vascular aging actually is

Vascular aging is defined by structural and functional change in the blood vessels, with arterial stiffness and endothelial dysfunction as its two key components, and it raises the risk of cardiovascular and other age-related disease. The molecular pathways identified as central include oxidative stress and inflammation (Roth et al., 2023).

Two things follow from that definition. The first is that vascular aging is a process rather than an event, so there are several places to intervene. The second is that it is measurable in a living person through arterial stiffness, which is why it is one of the more tractable parts of aging biology.

Step one: the lining stops making nitric oxide

The enzyme that produces nitric oxide in the vessel lining is called eNOS. Under oxidative stress it does something unfortunate called uncoupling, where the enzyme keeps running but produces reactive oxygen species instead of nitric oxide. The machine that made the useful thing starts making the damaging thing, and it does so at the expense of the useful thing.

Astragaloside IV is the main active compound of astragalus. The review literature reports that it can prevent or reverse eNOS uncoupling, raise both eNOS and nitric oxide, reduce endothelial cell apoptosis under oxidative stress, and activate several enzymes of the antioxidant system (Meng et al., 2021).

Step two: the lining cells die under inflammatory stress

Oxidized LDL damages the lining, and one way lining cells die is pyroptosis, an inflammatory form of cell death driven by a protein assembly called the NLRP3 inflammasome. Cells dying this way burst and spill inflammatory signals, so the damage spreads outward.

Oxymatrine, the alkaloid from Ku Shen, was tested on human umbilical vein endothelial cells injured by oxidized LDL. It suppressed NLRP3 inflammasome-mediated pyroptosis by activating SIRT1 and Nrf2, with antioxidant enzyme activity recovering alongside (Jin et al., 2021).

SIRT1 is a longevity gene and Nrf2 governs the inducible antioxidant response, so this is a compound reaching a vascular problem through general aging machinery. Our article on Ku Shen covers the rest of its file.

Step three: immune cells turn into foam

When oxidized cholesterol accumulates in the vessel wall, macrophages arrive to clear it. They take in more than they can process, fill with lipid droplets, and become what pathologists call foam cells, which then lodge in the wall as the beginnings of plaque.

Clematichinenoside AR, from Clematis chinensis, was tested in macrophages exposed to oxidized LDL. It reduced foam cell formation, measured directly by Oil Red staining, lowered cholesterol levels in the cells, and reduced inflammatory cytokine expression (Diao et al., 2021).

Step four: plaque builds and the artery stiffens

This step is where vascular aging becomes measurable. Aortic compliance describes how much the main artery gives when blood is pushed into it, and losing that springiness is the stiffening half of the standard definition.

Dehydrocorydaline, an alkaloid from Corydalis yanhusuo, was given to ApoE-deficient mice, a strain that develops atherosclerosis reliably. It inhibited plaque development, improved aortic compliance, increased plaque stability, and reduced systemic and vascular inflammation (Wen et al., 2022).

Improving compliance is the result worth noting. Plaque burden and arterial stiffness are related but separate, and stiffness is the one that maps directly onto the vascular aging definition.

Step five: platelets become quick to clot

The last step is the one that turns a slow problem into a sudden one. Aged, inflamed vessels make platelets easier to activate.

Tanshinone IIA, from danshen, was studied against a specific trigger. Platelets exposed to the inflammatory signal IL-6 shed small fragments called microvesicles, and those fragments activate other platelets through CD36 and the MKK4/JNK2 signalling route. Tanshinone IIA prevented platelet activation and downregulated that pathway (Wang et al., 2020).

IL-6 rises with age as part of chronic low-grade inflammation, so this links inflammaging to clotting risk through a defined route.

The whole-animal test

The five above are mechanisms. One study took a whole extract and measured the finished outcome.

An ethanol extract of Schisandra chinensis fruit was given to rats with experimentally induced atherosclerosis for three weeks, with simvastatin as the active comparator, and the extract was quantified by HPLC for schisandrin, schisandrin A and schisandrin B so the dose is defined (Chen et al., 2018). Running against a statin rather than against nothing is the harder test, and quantifying the markers means the preparation could be reproduced.

What the pattern shows

Six compounds from six unrelated plants, landing on five consecutive steps of one cascade, is the clearest worked example of the argument in our piece on multi-target formulations. Nobody designed this spread. It emerged because different research groups chased different parts of the same problem.

It also shows what a thoughtful formula would have to look like. Most cardiovascular supplement blends stack antioxidants, which addresses one step repeatedly. The literature here suggests a different shape: something for the lining, something for the inflammatory cell death, something for lipid handling in macrophages, something for stiffness, something for platelets. Whether such a combination would work is untested. The point is that the sequence gives you a way to ask the question.

Limitations

Every result above is from cells or animals, none of these compounds has a human trial for vascular aging or arterial stiffness, and the astragaloside IV evidence is a review of preclinical work rather than a single experiment; a compound active at a given concentration in a dish has not been shown to reach that concentration in a person after oral dosing.

Citations

[1] Roth et al. Pharmacological modulation of vascular ageing: a review from VascAgeNet. Ageing Res Rev. 2023. PMID 37956927
[2] Meng et al. Molecular mechanism of astragaloside IV in improving endothelial dysfunction of cardiovascular diseases mediated by oxidative stress. Oxid Med Cell Longev. 2021. PMID 34840664
[3] Jin X, Fu W, Zhou J, et al. Oxymatrine attenuates oxidized low-density lipoprotein-induced HUVEC injury by inhibiting NLRP3 inflammasome-mediated pyroptosis via activation of the SIRT1/Nrf2 signaling pathway. Int J Mol Med. 2021;48(4):187. PMID 34368883
[4] Diao et al. Clematichinenoside AR alleviates foam cell formation and the inflammatory response in ox-LDL-induced RAW264.7 cells. Inflammation. 2021. PMID 33151398
[5] Wen et al. Antiatherosclerotic effect of dehydrocorydaline on ApoE-/- mice: inhibition of macrophage inflammation. Acta Pharmacol Sin. 2022. PMID 34552216
[6] Wang et al. Tanshinone IIA prevents platelet activation and down-regulates CD36 and MKK4/JNK2 signaling pathway. BMC Cardiovasc Disord. 2020. PMID 32059638
[7] Chen et al. Ethanol extract of Schisandrae chinensis fructus ameliorates the extent of experimentally induced atherosclerosis in rats. Pharm Biol. 2018. PMID 31070526

These statements have not been evaluated by the Food and Drug Administration. The compounds discussed here are research subjects and nothing on this page is a recommendation to use any of them. Nothing here is intended to diagnose, treat, cure or prevent any disease.